All In Biotech

Drug Trial Radar · NCT06611696

Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis

Avacopan With Short-term Reduced-dose Glucocorticoids vs Reduced-dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-associated Vasculitis

Last checked: Nov 20, 2026Latest source record: May 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Nov 15, 2024

Primary completion

Mar 31, 2027

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Chiba UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Kissei Pharmaceutical Co., Ltd.; International University of Health and Welfare
First posted
Sep 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if avacopan in combination with short-term (4 weeks) reduced-dose glucocorticoid and rituximab works to treat patients with newly-onset ANCA-associated vasculitis. It will also learn about the long-term safety of avacopan. The main questions it aims to answer are: Is avacopan in combination with short-term reduced-dose glucocorticoid and rituximab as effective as the combination of 20 week reduced-dose glucocorticoid and rituximab in the proportion of the patients achieving remission? Does avacopan lower the relapse rate compared to the 6 monthly rituximab maintenance therapy? What medical problems do participants have when taking long-term avacopan? Participants will: Be treated with avacopan in combination with short-term (until 4 weeks) reduced-dose glucocorticoid and rituximab (at 0 week) or reduced-dose glucocorticoid (until 20 weeks) and rituximab (at 0, 26, 52 and 78 weeks). Be assessed at 0, 4, 8, 16, 26, 52, 78 and 104 weeks regarding disease status (remission/relapse), disease activity by Birmingham Vasculitis Activity Score ver3, disease damage by Vasculitis Damage Index and adverse events. The primary endpoint is remission rates at 26 weeks.

Conditions

  • ANCA Associated Vasculitis (AAV)

Interventions

  • Avacopan, prednisolone and rituximabDrug

    Patients in the avacoapn group will be treated with avacoapn, short-term reduced-dose prednisolone and rituximab.

  • Prednisolone and rituximabDrug

    Patients in the glucocorticoid arm will be treated with reduced-dose prednisolone and rituximab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportions of patients achieving remissionTime frame: 26 weeks

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan · Not yet recruiting

  • Asahi General Hospital

    Asahi, Chiba, Japan · Recruiting

  • Chiba Aoba Municipal Hospital

    Chiba, Chiba, Japan · Recruiting

  • Chiba University

    Chiba, Chiba, Japan · Recruiting

  • Chiba Rosai Hospital

    Ichihara, Chiba, Japan · Recruiting

  • Kameda Medical Centre

    Kamogawa, Chiba, Japan · Recruiting

  • International University of Health and Welfare

    Narita, Chiba, Japan · Recruiting

  • Japanese Red Cross Narita Hospital

    Narita, Chiba, Japan · Recruiting

  • Gunma University

    Maebashi, Gunma, Japan · Recruiting

  • Kagawa University

    Hiragi, Kagawa-ken, Japan · Recruiting

  • St.Marianna University School of Medicine

    Kawasaki, Kanagawa, Japan · Recruiting

  • Tohoku Univerisity

    Sendai, Miyagi, Japan · Recruiting

  • Nagasaki University

    Nagasaki, Nagasaki, Japan · Recruiting

  • Okayama University

    Okayama, Okayama-ken, Japan · Recruiting

  • Kitano Hospital

    Osaka, Osaka, Japan · Recruiting

  • Saitama Medical University

    Kawagoe, Saitama, Japan · Recruiting

  • Dokkyo Medical University

    Mibu, Tochigi, Japan · Recruiting

  • Juntendo Univeristy

    Bunkyoku, Tokyo, Japan · Recruiting

  • Kyorin University

    Mitaka, Tokyo, Japan · Recruiting

  • Toho University

    Ōta-ku, Tokyo, Japan · Recruiting

  • Teikyo University

    tabashi City, Tokyo, Japan · Recruiting

  • Yamanashi University

    Chuo-shi, Yamanashi, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.